The majority of our patients (178/232 = 76.8%) were of the “favorable” breast carcinoma subtype (ER+ and/or PR+, HER2−), subdivided to the luminal A-like and luminal B/HER2 negative-like subtypes. The gene discussed is ERBB2; the disease is breast carcinoma.